Cell line · CVCL_B288
Papers258
1 to 20 of 258
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| PubMed 43000531 | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 42999633 | Immunotargets Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| IFNAR1 stabilization sustains CD8+ T cell persistence in IFN-high colorectal cancer liver metastases. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MAGI3 Acts as an Intestinal Epithelial Gatekeeper in Inflammation-Associated Colorectal Cancer by Suppressing the STAT3-CCL2 Axis and TAM-Mediated Immunosuppression. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Loss of Lepr in Fibroblasts Drives Tumor Development by Promoting Macrophage Infiltration. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Liver-specific amino acid metabolism impacts on efficacy of cancer immunotherapy. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Compartment-specific PPARδ activity controls the outcome of cancer-immune cell competition and immunotherapy efficacy. | Nat Immunol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| AIM2 in tregs restrains anti-PD-1 efficacy by reinforcing immune suppression in MC38 colorectal cancer. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MIIP Inhibits Colorectal Cancer Progression by Modulating Neutrophils Infiltration and Neutrophil Extracellular Trap Formation. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Intravenously deliverable oncolytic virus VET3-TGI favorably alters the tumor microenvironment. | J Immunother Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment. | J Exp Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Surface-engineered milk-derived extracellular vesicles enable oral miRNA therapy against immunosuppressive pancreatic cancer. | Mater Today Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The long non-coding RNA-encoded microprotein MKKS3 drives colorectal cancer chemoresistance. | Exp Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Secreted ADAMTSL4 Activates Latent TGFβ1 to Drive Cancer Cachexia. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Neutralizing the IL12/IL23 p40 Subunit Prevents Immune Checkpoint Blockade Toxicity without Compromising Antitumor Efficacy. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lactobacillus salivarius potentiates gastrointestinal cancer immunotherapy through its metabolite chenodeoxycholic acid. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer. | Biomolecules | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PDL1-driven self-amplifying drug homing with immune homeostasis restoration. | Mater Today Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| OTUD5 maintains STAT1/2 stability and promotes IFNγ-driven intestinal inflammation. | J Biol Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cblb Gene Editing in T Cells Sustains Expansion and Immunogenic CAR T Tumor Killing Under Chronic Antigenic Stimulation. | Cells | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_B288/papers